Dana-Farber Cancer Institute and the Lifespan Cancer Institute have agreed to renew their strategic alliance to advance cancer treatment and research. Dana-Farber and the Lifespan Cancer Institute signed an initial agreement in 2017.
Dana-Farber Cancer Institute
Advertisement
Articles by Dana-Farber Cancer Institute
The Gairdner Foundation has announced that Stuart H. Orkin, MD, is one of the 2022 Canada Gairdner Award laureates for seminal discoveries and contributions to biomedical science.
Dana-Farber Cancer Institute is launching a year-long celebration of its 75th anniversary to highlight its history and progress in cancer care and transformative cancer research.
A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non–small cell lung cancer that was resistant to a single immunotherapy agent.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5